RT Journal Article
SR Electronic
T1 Lack of Antiviral Activity of Darunavir against SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.03.20052548
DO 10.1101/2020.04.03.20052548
A1 De Meyer, Sandra
A1 Bojkova, Denisa
A1 Cinatl, Jindrich
A1 Van Damme, Ellen
A1 Buyck, Christophe
A1 Van Loock, Marnix
A1 Woodfall, Brian
A1 Ciesek, Sandra
YR 2020
UL http://medrxiv.org/content/early/2020/04/08/2020.04.03.20052548.abstract
AB Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. DRV showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100 μM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 μM). Overall, the data do not support the use of DRV for treatment of COVID-19.Competing Interest StatementSandra De Meyer, Christophe Buyck, Ellen Van Damme, Marnix Van Loock and Brian Woodfall are employees and may be stock owners of Johnson and Johnson. Sandra Ciesek received research funding from Janssen for this research.Clinical TrialThis is an in-vitro studyFunding StatementFunding for this study was provided by Janssen Pharmaceutica.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.